Edwards Lifesciences
Corporation’s (EW) fourth-quarter 2013 adjusted earnings
per share (EPS) rose 1.1% year over year to 91 cents, reflecting a
beat of 9.6% over the Zacks Consensus Estimate. Fiscal 2013
adjusted earnings of $3.13 per share showed a robust 16.4% growth
from the year-ago figure and also remained well ahead of the Zacks
Consensus Estimate of $3.05. Apart from healthy sales growth, EPS
growth was boosted by a reduced share count.
However, without taking into
consideration the one-time items, reported EPS for the fourth
quarter came in at 68 cents, up 11.7% year over year. Full year
reported EPS surged 38.7% from the prior year to reach $3.44.
Revenue
Details
Edwards reported sales of $536
million, up 5.1% year over year (considering foreign exchange
fluctuations and the transcatheter heart valves (THV) sales return
reserve, underlying growth was 10.3%). The top line was on par with
the Zacks Consensus Estimate. Sales for full year 2013 came in at
$2.05 billion, registering an increase of 7.7% (or up 10.8% on an
underlying basis). Revenues were, once again, in line with the
Zacks Consensus Estimate. The figure also remained within the
company provided guidance range.
During 2013, Edwards launched many
new products, demonstrated strong clinical data and made
significant progress on several key developments indicating
sustainable future growth at the company.
Domestically, sales amounted to
$239.1 million, up 9.6% year over year (underlying growth rate)
while internationally, sales were $296.9 million, up 10.9% year
over year. In the overseas market, sales in Europe improved 13.9%
to $162.3 million while revenues from rest of the world were up
10.6% at CER to $67.0 million. Sales in Japan increased 6.1% to
$67.6 million.
Segments
In fourth-quarter 2013, surgical
heart valve therapy product group reported sales of $207.0 million,
up 4.7% year over year (up 7.6% on an underlying basis). The
quarter’s performance reflects solid contributions from the U.S.
and Europe. Also, strong sales of Intuity valve in Europe
contributed to growth.
Globally, THV product group
reported sales of $183.9 million, up 14.2% year over year (up 21.6%
on an underlying basis). Revenues of this product group were mainly
driven by healthy growth in Europeon the back of greater adoption
of THV and the expected contribution from the Sapien valve in the
U.S.
Critical care product group sales
were $145.1 million, down 4.4% year over year (up 1.8% on an
underlying basis). Strength in most of the regions globally was
tempered by the continued reduction of distributor inventories in
China and the ongoing exit of the Access product line.
Margins
In the fourth quarter, gross margin
contracted 250 basis points (bps) to 72.9%. Despite a more
profitable product mix, margin contraction was primarily due to
reduced benefit from foreign exchange hedges, the impact from the
sales return reserve and higher manufacturing costs for new THV
product launches in the U.S. and Europe.
Selling, general and administrative
expense increased 7.1% year over year to $190.5 million (or 35.5%
of sales), primarily due to the U.S. Medical Device Excise Tax and
transcatheter valve launch-related expenses in Japan, partially
offset by foreign exchange.
Research and development
expenditure increased 4.9% year over year to $78.6 million or 14.7%
of sale. The higher expenses were on account of additional
investments in multiple heart valve clinical studies. With higher
operating expenses, adjusted operating margin contracted 319 bps to
22.6% in the quarter.
Cash Position
Edwards exited the fiscal with
cash, cash equivalents and short-term investments of $936.9 million
compared with $521.4 million at the end of 2012. Long-term debt of
the company was $593.1 million compared with $189.3 million at the
end of 2012.
Operating cash flow was $111.3
million while capital spending came in at $20.1 million.
Consequently, free cash flow was $91.2 million in the fourth
quarter. Edwards repurchased almost 6.8 million shares for $496.9
million during the quarter. Edwards’ consistent share buyback
activity reduced outstanding shares by 5.8% from the year-ago
quarter, leading to a positive impact on the bottom line.
Guidance
Following the fourth quarter,
Edwards maintained its guidance for 2014 which it first announced
at the annual investor conference last December. The company
continues to expect adjusted EPS for 2014 in a wide range around
$3.00 on revenues of $2.05 billion to $2.25 billion
(unchanged).
The current Zacks Consensus
estimate for EPS and revenues of $3.00 and $2.14 billion
respectively remain in line with the company’s projection.
Moreover, 2014 free cash flow (excluding special items) is still
expected to remain within $325 million and $425 million. Also full
year diluted shares outstanding should remain within 107 million
and 109 million.
For the first quarter of 2014,
adjusted EPS is expected to remain within 61 cents to 71 cents on
revenues of $500 million to $550 million. The Zacks Consensus
Estimate for EPS of 72 cents exceeds the guidance range while
revenues of $528 million fall within the range.
Our Take
Edwards exited the year 2013 with
several positive takeaways including the recent European CE mark
approval for its latest transcatheter aortic valve, Sapien 3;
reimbursement for Sapien XT in Japan (effective Oct 1, 2013);
regulatory approval for Sapien in Australia and Sapien XT in
Canada. Edwards is also optimistic about the expected U.S. approval
of the company’s next generation Sapien XT valve in the first half
of 2014.
Nonetheless, we are worried about
the earlier-than-expected FDA approval of its peer
Medtronic Inc.’s (MDT) less-invasive heart valve,
CoreValve. This approval will enable the launch of CoreValve in the
U.S. market – the only U.S. rival of Edwards’ Sapien. CoreValve –
whose market price is expected to remain on par with that of Sapien
– should bring down Edwards' revenue growth rate significantly by
weakening its dominance in the U.S market.
Edwards currently carries a Zacks
Rank #5 (Strong Sell). Some of the better-placed medical devices
stocks such as Covidien plc (COV) and
Stryker Corporation (SYK), which carry a Zacks
Rank #2 (Buy), are worth considering.
COVIDIEN PLC (COV): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
STRYKER CORP (SYK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Edwards Lifesciences (NYSE:EW)
Historical Stock Chart
From Aug 2024 to Sep 2024
Edwards Lifesciences (NYSE:EW)
Historical Stock Chart
From Sep 2023 to Sep 2024